menu
    • menu

    Company profile for Apeiron Biologics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    APEIRON is a privately-held European biotech company based in Vienna, Austria, focused on the discovery and development of novel cancer immunotherapies. APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients and out-licensed global, exclusive rights to this product to EUSA Pharma Ltd. APEIRON now leverages its proprietary master checkpo...
    APEIRON is a privately-held European biotech company based in Vienna, Austria, focused on the discovery and development of novel cancer immunotherapies. APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients and out-licensed global, exclusive rights to this product to EUSA Pharma Ltd. APEIRON now leverages its proprietary master checkpoint blockade mechanism to enable the human body’s natural defense mechanisms to fight tumors.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Apeiron BiologicsAustria Flag
    Country
    Country
    Austria
    Address
    Address
    APEIRON Biologics AG Campus-Vienna-Biocenter 5 1030 Vienna
    Telephone
    Telephone
    +43 1 86565 77
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.apeiron-biologics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ligand to Acquire APEIRON Biologics AG for $100 Million
    Ligand to Acquire APEIRON Biologics AG for $100 Million

    08 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240706652097/en

    BUSINESSWIRE
    08 Jul 2024
    Share Share
    APEIRON Respiratory Therapies announces results from PI trial of inhaled APN01
    APEIRON Respiratory Therapies announces results from PI trial of inhaled APN01

    02 Nov 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/11/03/2547255/0/en/APEIRON-Respiratory-Therapies-announces-positive-results-from-Phase-I-trial-of-inhaled-APN01.html

    GLOBENEWSWIRE
    02 Nov 2022
    Share Share
    APEIRON shareholders approve new group structure geared towards
    APEIRON shareholders approve new group structure geared towards

    25 Apr 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/04/26/2428692/0/en/APEIRON-shareholders-approve-new-group-structure-geared-towards-enabling-innovation-and-growth.html

    GLOBENEWSWIRE
    25 Apr 2022
    Share Share
    Apeiron Biologics begins phase 1 trial to treat Covid-19 with inhaled APN01
    Apeiron Biologics begins phase 1 trial to treat Covid-19 with inhaled APN01

    13 Oct 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=143214&sid=2

    PHARMABIZ
    13 Oct 2021
    Share Share
    Apeiron Biologics begins phase 1b trial of APN401 for treatment of solid tumors
    Apeiron Biologics begins phase 1b trial of APN401 for treatment of solid tumors

    07 Jul 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=139805&sid=2

    PHARMABIZ
    07 Jul 2021
    Share Share
    Apeiron announces phase 2 trial of APN01 shows clinical benefits
    Apeiron announces phase 2 trial of APN01 shows clinical benefits

    15 Mar 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=136136&sid=2

    PHARMABIZ
    15 Mar 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search